DeepMed Research

Guangdong Provincial People's Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1946-01-01

Employees: -

Market Cap: -

Website: http://www.gdghospital.org.cn

Clinical Trials

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 25

Registration Number: NCT06734182

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer

Early Phase 1

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: mRNA Neoantigen Vaccine
Drug: Adebrelimab

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT06735508

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

NK010 or NK042 in Combination with Rituximab for Refractory Systemic Lupus Erythematosus/lupus Nephritis

Phase 1

Recruiting

Conditions: Refractory Systemic Lupus Erythematosus
Refractory Lupus Nephritis

Interventions: Biological: NK 010 or NK042
Drug: Rituximab

First Posted Date: 2024-11-06

Last Posted Date: 2025-03-12

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 18

Registration Number: NCT06676631

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdomg, China

Effectiveness and Safety of Adjuvant Software Based on Virtual Reality for Post-thoracoscopic Surgery Pain

Not Applicable

Recruiting

Conditions: Virtual Reality
Video-assisted Thoracic Surgery
Acute Postoperative Pain

Interventions: Device: VR-assisted postoperative analgesia

First Posted Date: 2024-08-28

Last Posted Date: 2024-08-28

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 215

Registration Number: NCT06574451

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
🇨🇳
Ruijing Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Maoming People's Hospital, Maoming, Guangdong, China

and more 1 locations

Surgical Treatments of Tricuspid Valve Regurgitation After Cardiac Surgery

Recruiting

Conditions: Tricuspid Valve Regurgitation; Complications, Longterm Outcome

Interventions: Procedure: Huanlei Huang

First Posted Date: 2024-08-15

Last Posted Date: 2024-08-15

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 375

Registration Number: NCT06554119

Locations: 🇨🇳
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China

Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors

Not Applicable

Not yet recruiting

Conditions: Sarcoma, Soft Tissue
Sarcoma, Spindle Cell

Interventions: Device: Biodegradable Magnesium Metal Clips

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 98

Registration Number: NCT06550765

Locations: 🇨🇳
Guangdong provincial people's hospital, Guangzhou, Guangdong, China

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT06547476

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Phase 3

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Drug: 9 cycles of Camrelizumab as adjuvant therapy.

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-04

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 310

Registration Number: NCT06533384

Locations: 🇨🇳
Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China

Dietary Protein Sources and Glycemic Variability

Not Applicable

Not yet recruiting

Conditions: Obesity
Diabetes
Metabolic Disease
Overweight
Dietary Protein

First Posted Date: 2024-07-29

Last Posted Date: 2024-07-31

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 96

Registration Number: NCT06525441

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase 4

Recruiting

Conditions: Soft Tissue Sarcoma
Doxorubicin
Radiotherapy

Interventions: Drug: Anlotinib

First Posted Date: 2024-07-18

Last Posted Date: 2024-08-12

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 39

Registration Number: NCT06506838

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Guangdong provincial people's hospital, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy